Clinical translation of radiotheranostics for precision oncology

Radiotheranostics combines disease-specific molecular imaging and radionuclide therapy. We present new and promising targets, tracers and isotopes for radiotheranostics and outline the road to clinical translation of the 177Lu–LNC1004 radiopharmaceutical, which has recently been approved by the US Food and Drug Administration (FDA) for a phase I clinical trial.